ISSAR is focusing on evolution of science to bring forward a novel peptide therapy for one of the highest contributors of pain and physical disability worldwide: Rheumatoid Arthritis.
ISSAR has developed a novel synthetic peptide therapeutically targeting joints, which is currently under preclinical trials. ISSAR is hoping to improve the quality of life for patients suffering with Rheumatoid Arthritis in the near future.
Therapeutic potential of peptides for Rheumatoid Arthritis
Studies have shown promising results with the new immunomodulatory treatment approaches. Researchers have identified convincing results for the potential of peptide therapeutics for patients affected with Rheumatoid Arthritis. Since these naturally occurring peptides play a dual role of modulation and regulation of the abnormal immune responses and inflammatory mediators, they offer notable benefits over some of the current approaches used for Rheumatoid Arthritis.
ISSAR’s IS-181 for Rheumatoid Arthritis
In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis (RA) was observed to be the 42nd highest contributor of global physical disability.
It is an autoimmune disease which manifests as painful swelling of joints, particularly in the wrists, hands and knees accompanied by fever, fatigue, stiffness in one or more joints and weakness.
ISSAR has developed a novel peptide drug for angiogenesis related diseases and inflammatory disorders. This novel peptide drug designated as IS-181 targets the VEGFR-2 which is the major receptor for angiogenesis function.
IS-181 causes modulation of VEGFR-2 receptors which are the major receptors for angiogenesis function, through down-regulation of MAPK/ p38/ ERK1/2 pathways.